Hartmut Goldschmidt
Goldschmidt, Hartmut 1956-
Goldschmidt, Hartmut
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
VIAF ID: 54739721 (Personal)
Permalink: http://viaf.org/viaf/54739721
Preferred Forms
-
100 1 _
‡a
Goldschmidt, Hartmut
-
100 1 _ ‡a Goldschmidt, Hartmut
-
100 1 _ ‡a Goldschmidt, Hartmut
-
100 1 _
‡a
Goldschmidt, Hartmut
-
100 1 _
‡a
Goldschmidt, Hartmut
-
100 1 _
‡a
Goldschmidt, Hartmut
‡d
1956-
-
100 0 _
‡a
Hartmut Goldschmidt
4xx's: Alternate Name Forms (6)
5xx's: Related Names (5)
- 551 _ _
‡a
Forst (Lausitz)
‡4
ortg
‡4
https://d-nb.info/standards/elementset/gnd#placeOfBirth
- 551 _ _
‡a
Heidelberg
‡4
ortw
‡4
https://d-nb.info/standards/elementset/gnd#placeOfActivity
- 510 2 _
‡a
Ludolf-Krehl-Klinik
- 510 2 _
‡a
Universität Heidelberg
‡b
Medizinische Fakultät
‡4
affi
‡4
https://d-nb.info/standards/elementset/gnd#affiliation
‡e
Affiliation
- 510 2 _
‡a
Universitätsklinikum Heidelberg
‡b
Zentrum für Innere Medizin
‡4
affi
‡4
https://d-nb.info/standards/elementset/gnd#affiliation
‡e
Affiliation
Works
| Title | Sources |
|---|---|
| Bedeutung der freien Leichtketten im Serum im Rahmen der Diagnostik und Remissionsbeurteilung bei neu diagnostizierten und mit einer Bortezomib-basierten Induktionstherapie behandelten Patienten mit Multiplem Myelom im Rahmen der MM5 Studie |
|
| Effet de l'acupuncture comparée à l'acupuncture placebo à MC6 comme prophylaxie additionnelle antiantiémétrique dans les chimiothérapies à haute dose et les transplantations autologues de cellules souche de sang périphérique |
|
| Elotuzumab beim Multiplen Myelom gezielte Immunaktivierung durch SLAMF7-Antikörper |
|
| A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis |
|
| Kurzlehrbuch Innere Medizin |
|
| Multiple myeloma |
|
| Pelottierung der A. thoracica descendens durch einen Zementsporn: endovaskuläre Behandlung nach Kyphoplastie |
|
| Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9 |
|
| Platelet Count before Peripheral Blood Stem Cell Mobilization Is Associated with the Need for Plerixafor But Not with the Collection Result. |
|
| Potential therapeutic targets in plasma cell disorders: A flow cytometry study. |
|
| Preclinical efficacy of sepantronium bromide |
|
| Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study |
|
| Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load |
|
| Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. |
|
| Radiotherapy of solitary plasmacytoma. |
|
| Rapid progression of left ventricular wall thickness predicts mortality in cardiac light-chain amyloidosis |
|
| Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized study. |
|
| Respiratory muscle weakness and inefficient ventilation in heart failure due to light-chain amyloidosis |
|
| Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial |
|
| The role of fluorescence in situ hybridization and gene expression profiling in myeloma risk stratification. |
|
| The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor |
|
| Sensitivity of whole-body CT and MRI versus projection radiography in the detection of osteolyses in patients with monoclonal plasma cell disease. |
|
| Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac light-chain amyloidosis |
|
| Staging monoclonal plasma cell disease: comparison of the Durie-Salmon and the Durie-Salmon PLUS staging systems |
|
| [Stem cells in hematology and oncology] |
|
| Storage Duration of Autologous Stem Cell Preparations Has No Impact on Hematopoietic Recovery after Transplantation |
|
| Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up |
|
| Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. |
|
| Therapie des multiplen Myeloms : eine retrospektive Analyse von 185 konsekutiven Patienten mit besonderer Berücksichtigung der autologen Hochdosis-Chemotherapie |
|
| Timing of the high-dose therapy in the area of new drugs. |
|
| Transcriptional regulation of the vascular endothelial glycome by angiogenic and inflammatory signalling |
|
| Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens. |
|
| Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome. |
|
| Zur Klinik der autoimmunhämolytischen Anämien |
|
